Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data
Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data
Stock price for Viking Therapeutics, Inc. (NASDAQ: VKTX) jumped 111.23% this current session, reaching $81.28 – a promising sign. Recent favorable clinical outcomes correlate with this increase in VKTX stock price.
维京疗法公司（纳斯达克股票代码：VKTX）的股价在本交易日上涨了111.23％，至81.28美元，这是一个令人鼓舞的迹象。最近良好的临床结果与VKTX股价的上涨相关。
Viking Therapeutics (VKTX) disclosed encouraging Phase 2 trial findings for VK2735, a medication targeting GLP-1 and GIP receptors, aiming to tackle obesity and metabolic issues. The Phase 2 VENTURE trial has effectively met its primary objective along with all secondary goals, with subjects administered VK2735 demonstrating statistically significant declines in body mass compared to those on placebo.
Viking Therapeutics（VKTX）披露了令人鼓舞的 VK2735 二期试验结果。是一种靶向 GLP-1 和 GIP 受体的药物，旨在解决肥胖和代谢问题。2 期 VENTURE 试验有效地实现了其主要目标和所有次要目标，与服用安慰剂的受试者相比，服用 VK2735 的受试者的体重有统计学上的显著下降。
Furthermore, the study indicates that VK2735 treatment is well-tolerated and safe, with most treatment-related adverse events categorized as mild or moderate. Viking intends to engage with the FDA to discuss subsequent developmental steps for VK2735 based on these findings. Patients subjected to weekly VK2735 doses exhibited statistically notable reductions in average body mass after a 13-week regimen, ranging up to 14.7% from baseline.
此外，该研究表明，VK2735 治疗耐受性良好且安全，大多数与治疗相关的不良事件归类为轻度或中度。维京打算与美国食品药品管理局合作，根据这些发现讨论 VK2735 的后续开发步骤。每周接受 VK2735 剂量的患者在接受为期 13 周的疗程后，平均体重在统计学上显著下降，与基线相比高达 14.7%。
These patients also displayed statistically significant declines in average body mass compared to the placebo group, reaching up to 13.1%. Significant differences relative to both baseline and placebo were evident across all dosages starting from the first week and persisting throughout the 13-week treatment period. Weight reduction exhibited a progressive trend during the study duration, with no plateau observed at the 13-week mark.
与安慰剂组相比，这些患者的平均体重也出现了统计学上的显著下降，降至13.1％。从第一周开始，所有剂量与基线和安慰剂的显著差异都很明显，在整个13周的治疗期内持续存在。在研究期间，体重减轻呈渐进趋势，在13周时未观察到停滞状态。
All VK2735 dosage levels showcased statistically significant variances compared to placebo regarding the key secondary endpoint, which assessed the proportion of patients achieving at least a 10% weight reduction. Remarkably, up to 88% of patients in VK2735 treatment cohorts achieved this milestone, compared to a mere 4% for the placebo group. VK2735 demonstrated commendable safety and tolerability profiles following a 13-week regimen of once-weekly dosing.
与安慰剂相比，所有 VK2735 剂量水平在关键次要终点方面都显示出统计学上的显著差异，后者评估了体重减轻至少 10% 的患者比例。值得注意的是，在 VK2735 治疗组中，多达 88% 的患者实现了这一里程碑，而安慰剂组的这一比例仅为 4%。在为期 13 周的每周给药方案之后，VK2735 表现出值得称道的安全性和耐受性。
Discontinuation rates in the VENTURE study remained low and evenly distributed between patients treated with VK2735 and those administered placebo. In total, 23 patients (13%) discontinued treatment during the study, with 5 (14%) in the placebo cohort and 18 (13%) among VK2735-treated cohorts.
VENTURE 研究中的停药率仍然很低，并且在接受 VK2735 治疗的患者和服用安慰剂的患者之间分布均匀。在研究期间，共有23名患者（13％）停止治疗，其中5名（14％）在安慰剂队列中，18名（13％）在接受VK2735治疗的队列中。